Grail股价暴跌,因NHS-Galleri癌症血液检测关键试验未达主要终点。
Grail stock craters as key NHS-Galleri cancer blood test trial fails to hit primary endpoint
生物技术与制药领域的最新动态
Grail stock craters as key NHS-Galleri cancer blood test trial fails to hit primary endpoint
Mainz Biomed looks to shed ColoAlert, shifts focus in US
Chutes & Ladders—Roche taps Aussie oncologist to lead early research
Biohaven charts comeback path after FDA blow, placing bets on obesity
Candel glows brighter with $100M RTW royalty deal to fund prostate cancer drug's launch
Daiichi picks former Novartis CMO John Tsai to head up R&D
White House frustration may have fueled FDA’s Moderna walkback: Politico
Novartis winds down ph. 1 solid tumor program after lacking efficacy
Sanofi backs Altesa's $75M series B to bankroll antiviral's midstage rhinovirus study
Study finds blood test can predict age of Alzheimer's onset
J&J halts enrollment in phase 2 trial of AC Immune-partnered Alzheimer's therapy
GSK strikes 5-year deal with Jackson Laboratory focused on neurodegenerative disease research
NIH Director Jay Bhattacharya to take over as temporary CDC chief: media reports
Senate HELP Committee chair pitches proposals for FDA reform
Blood from pediatricians yields potential new medicines for respiratory viruses
FDA accepts filing for Moderna flu vaccine after swift rethink
Novartis finds natural partner in macrocycle biotech, inking $1.7B-plus cardio deal
Sensei steps back from brink by finding Faeth and its phase 2-stage cancer drug
Gut-focused Rasayana ingests gastrointestinal candidate in $36M licensing deal
Danaher buys patient monitoring specialist Masimo in $9.9B deal